Social Media Ideas for Biotech & Health

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

The State of Biotech 2026

The world of biotech is showing strong signs of growth and clinical impact while also experiencing new challenges. The explosion of AI is reshaping areas from drug discovery and pr...

New Biotech-Academia Partnership Approaches to Empower the Drug Development Ecosystem

Addressing shifts in the global clinical development ecosystem and how academia and biotech can better partner to develop new therapies for patients.

India’s lifesciences sector sees momentum build in innovation: BCG -HealthKois report

Private equity and venture capital investment in pharma rose 2.1x in five years to $ 731 million for the year ended March 2026, and biotech startups grew from roughly 1,500 to 2,40...

From confidence to capital: Positioning biotech for the next growth cycle

How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.

Life science industry in Geneva on a roll 

Geneva’s life science industry is bound to western Switzerland's Health Valley ecosystem but is also growing in and of itself. The post Life science industry in Geneva on a roll ...

<![CDATA[The Status of Nuvation Bio’s Pipeline]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

PARLIAMENT QUESTION: Contribution of BioE3 Policy

 PARLIAMENT QUESTION: Contribution of BioE3 PolicyPosted On: 06 AUG 2026 2:56PM by PIB DelhiThe Department of Biotechnology (DBT) has identified six thematic verticals in the BioE3...

Top biotech deals in August 2026 

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease. The post Top biotech deals in August 2026...

Biotech hub near Athens has lofty goals

Not far from Athens’ airport, a biotechnology hub has sprung up this year. The Athens LifeTech Park (ALTP) has been formed to support the full cycle of scientific innovation, from...

LIVX BY GITEX

Biotech. Life Sciences. Longevity. Age Tech. One global platform. LIVX is a first-of-its-kind global platform uniting the full healthcare ecosystem from biotech and life sciences t...

Biotech remains compelling even after major comeback. Here’s what investors say

The healthcare subsector has quietly become one of the most attractive opportunities this year.

<![CDATA[Moonwalk Biosciences Closes $70 Million Series B ]]>

Where Is Growth?

The 27 SEA biotech firms betting on cells, fermentation, and code

Southeast Asia’s startup story is usually told through ride-hailing, fintech, and e-commerce. But a quieter, stranger, and potentially more consequential sector is taking shape in...

Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience

<![CDATA[Nuvation Bio’s Global Strategy]]>

The biggest biotech funding rounds in August 2026

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August 2026. The post The biggest biotech funding rounds in A...

Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems

Discover the factors driving the success of Munich's biotech hub, which is now one of the leading clusters in Europe. The post Munich’s biotech hub: Inside one of Europe’s leading...

This week in charts: Biotech’s rebound is undeniable

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Top biotech deals in July 2026 

The top biotech deals of July 2026 were over small molecules, cell therapies, antibodies, RNA therapeutics, vaccines, and AI. The post Top biotech deals in July 2026  appeared fir...

SA Asks: What are the most promising oncology companies right now?

In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas

The job contraction, according to MassBio, reflected pipeline reprioritization by biopharma giants plus contraction by smaller companies, with R&D jobs dropping significantly b...